RxDoctor Payments Data

Adam Shestack, MD

Interventional Pain Medicine · Delray Beach, FLNPI 1588951974

Payments from drug & device makers

$6,730in general payments, 2019–2025

Across 200 payments — averaging $33.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GRT US Holding, Inc.$2K
  • Scilex Pharmaceuticals Inc.$1K
  • Boston Scientific$952
  • Abbott$891
  • Medtronic$544
  • Biotronik NRO, Inc.$383
  • plus $749 from 14 others

What the payments were for

  • Speaking & faculty fees$2,00030%
  • Food & beverage$4,73070%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,730 in reported general payments places this provider in the 55th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$317,450
Medicare patients
557
Services billed
8,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate33$18,394
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen365$9,675
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen324$7,078
Buprenorphine13$4,258
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$3,686
Oxycodone Hcl236$3,582
Tramadol Hcl346$2,535
Naloxone Hcl33$2,235
Tramadol Hcl ErTramadol Hcl40$2,159
Pregabalin105$2,139
Fentanyl21$1,623
Morphine Sulfate ErMorphine Sulfate68$1,415
Morphine Sulfate33$1,003
Acetaminophen-CodeineAcetaminophen With Codeine59$854
Gabapentin66$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$43$18,39433 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$13$9,465101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →